iron (III) chloride hexahydrate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 过渡金属盐
• 英文名称: iron (III) chloride hexahydrate
• 英文别名: ferric chloride hexahydrate；Iron(3+);chloride;hydrate
• 化学式: 3Cl*Fe*6H₂O
• 分子量: 270.298
• InChiKey: KZGUUILNVRKXEA-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -3.82
• 重原子数：
  3
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  iron (III) chloride hexahydrate 生成 shikonin dimethylformamide
  参考文献：
  名称：

  IRON/SHIKONIN NANO-COMPOSITE AND USE THEREOF AND METHOD FOR PREPARING THE SAME BY SUPERMOLECULAR SELF-ASSEMBLY

  摘要：

  An iron/shikonin nano-composite and a use thereof, and a method for preparing the same by supermolecular self-assembly, belonging to the technical field of functional materials. The composite consists of shikonin and ferric ions, wherein shikonin is coordinated with the ferric ions, and the hydroxyl and carbonyl groups in shikonin are coordinated with the ferric irons to form a complex, which is then assembled by π-π stacking and hydrophobic interactions to form a nano-composite which exhibits glutathione response. The composite is obtained by the following steps: adding an aqueous solution of a ferric salt and an organic solvent solution of shikonin in sequence into water while stirring at ambient temperature, continuously stirring at ambient temperature, and centrifuging the resulting mixture to purify, thereby obtaining an iron/shikonin nano-composite in the resulting solution.

  公开号：

  US20220071927A1
• 作为产物：
  描述：

  盐酸 、 iron(II) sulfate 以 水 为溶剂， 生成 ferrous(II) sulfate heptahydrate 、 iron (III) chloride hexahydrate
  参考文献：
  名称：

  Hensgen, Chemische Berichte, 1878, vol. 11, p. 1775 - 1775

  摘要：

  DOI：
• 作为试剂：
  描述：

  1-丙烯基苯 、 对甲苯磺酰胺 在 iron (III) chloride hexahydrate 作用下， 以 1,4-二氧六环 为溶剂， 反应 20.0h， 以11%的产率得到N-(1-phenylpropyl)-4-toluenesulfonamide
  参考文献：
  名称：

  FeCl3-catalyzed addition of nitrogen and 1,3-dicarbonyl nucleophiles to olefins

  摘要：

  A direct intermolecular addition of nitrogen and 1,3-dicarbonyl nucleophiles to stabilized double bonds (styrenes, 1,3-dienes, enol-ethers, sugars..) in the presence of green and inexpensive FeCl3 catalyst is described. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jorganchem.2010.09.031

文献信息

• 2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or
  申请人：Burroughs Wellcome Co.

  公开号：US04587341A1

  公开（公告）日：1986-05-06

  Compounds of the formula (II) ##STR1## or a salt, N-oxide or acyl derivative thereof, wherein Y is a group ##STR2## which is optionaly substituted and which optionally contain a nitrogen atom at one of positions A, B, C, D or E, in which the dotted line represents aromatic rings unless one of the rings contains a nitrogen atom in which case this ring is either aromatic or partially saturated, have antimicrobial properties. Processes for making these compounds, pharmaceutical compositions containing them and the medical use of the compounds are also disclosed.

  式（II）的化合物##STR1##或其盐、N-氧化物或酰基衍生物，其中Y是一个组##STR2##，可选择地被取代，并且可选择地在位置A、B、C、D或E之一含有氮原子，在这些位置中的虚线代表芳香环，除非其中一个环含有氮原子，在这种情况下，该环要么是芳香的，要么是部分饱和的，具有抗微生物特性。还公开了制备这些化合物的方法、含有它们的药物组合物以及这些化合物的医药用途。
• 12-hetero substituted 6,11-ethano-6,11-dihydrobenzo (b) quinolizinium
  申请人：Sterling Winthrop Inc.

  公开号：US05380729A1

  公开（公告）日：1995-01-10

  1-Hetero substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

  1-杂代替的6,11-乙烷-6,11-二氢苯并[b]喹啉盐，含有它们的药物组合物，以及利用它们治疗或预防神经退行性疾病或神经毒性损伤的方法。
• Quinoline compounds as H.sup.+ -ATPases
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06008230A1

  公开（公告）日：1999-12-28

  This invention relates to a quinoline compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group or aryl, each of which may be substituted with suitable substituent(s), A is --COHN-- or --NHCO--, n is an integer of 0 or 1, and ##STR2## is a group of the formula: ##STR3## In which R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined, and pharmaceutically acceptable salt thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prevention and/or the treatment of bone diseases caused by abnormal bone metabolism in human being or animals.

  这项发明涉及一种喹啉化合物，其化学式为：##STR1## 其中R.sup.1是吡啶基或芳基，每个基可能被适当的取代基取代，A是--COHN--或--NHCO--，n是0或1的整数，而##STR2## 是一个化学式为：##STR3## 的基团，其中R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7如定义，以及其药学上可接受的盐，制备方法，包含相同化合物的药物组合物，以及用于预防和/或治疗由人类或动物骨骼异常代谢引起的骨病的方法。
• Pyridine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05716971A1

  公开（公告）日：1998-02-10

  Pyridine derivatives of the formula ##STR1## wherein the ring A stands for an optionally further substituted benzene ring; the ring B stands for an optionally substituted pyridine ring; Q stands for hydroxyl group, or OQ.sup.1 or Q.sup.1 wherein Q.sup.1 stands for an optionally substituted aliphatic hydrocarbon group; and n denotes 0 or 1, or their salts, which have potassium.channel opening activity and are useful as therapeutic agents of circulatory diseases such as angina pectoris, hypertension, etc.

  式中的吡啶衍生物##STR1##其中环A代表一个可进一步取代的苯环；环B代表一个可取代的吡啶环；Q代表羟基，或OQ.sup.1或Q.sup.1，其中Q.sup.1代表一个可取代的脂肪烃基团；n表示0或1，或它们的盐，具有钾通道开放活性，并且可用作治疗剂，用于循环系统疾病，如心绞痛、高血压等。
• N-(1,3,4-thiadiazol-2-yl)benzamides
  申请人：Eli Lilly and Company

  公开号：US04141984A1

  公开（公告）日：1979-02-27

  A series of N-(1,3,4-thiadiazol-2-yl)benzamides, having a phenyl, naphthyl or hetero-aryl group at the 5-position of the thiadiazole ring and 2,6-substitution on the benzamide ring, are useful insecticides. The invention also provides insecticidal methods and compositions.

  一系列在噻二唑环的5位具有苯基、萘基或杂环芳基，并在苯甲酰胺环上有2,6-取代基的N-(1,3,4-噻二唑-2-基)苯甲酰胺类化合物，可用作杀虫剂。该发明还提供了杀虫方法和组合物。